Nektar Therapeutics (NKTR) Capital Expenditures (2010 - 2026)
Nektar Therapeutics' (NKTR) quarterly Capital Expenditures came in at $18000.0 in Q1 2026, up 800.0% year-on-year from $2000.0 in Q1 2025, and little changed quarter-over-quarter from $18000.0 in Q4 2025.
Nektar Therapeutics (NKTR) Capital Expenditures (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 800.0% year-over-year to $18000.0 in Q1 2026; TTM through Mar 2026 was $187000.0, a 85.76% decrease from a year earlier, with the FY2025 full-year figure at $171000.0, down 88.35% from the prior year.
- Capital Expenditures held at $18000.0 in Q1 2026 per NKTR's latest filing, from $18000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.2 million in Q1 2022 and bottomed at $2000.0 in Q1 2025.
- The 5-year median for Capital Expenditures is $181000.0 (2022), against an average of $482235.3.
- Across the five-year window, Capital Expenditures soared 1918.18% in 2024 and sank 98.73% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at $512000.0 in 2022, then tumbled by 53.71% to $237000.0 in 2023, then soared by 93.67% to $459000.0 in 2024, then slumped by 96.08% to $18000.0 in 2025, then changed by 0.0% to $18000.0 in 2026.
- Per Business Quant, the three latest NKTR Capital Expenditures figures stand at $18000.0 (Q1 2026), $18000.0 (Q4 2025), and $114000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Nektar Therapeutics | 2.04 Bn | 1.48 Bn | 3.16 Mn | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 114,000.00 |
| Sep 30, 2025 | 114,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 459,000.00 |
| Dec 31, 2024 | 459,000.00 |
| Sep 30, 2024 | 666,000.00 |
| Sep 30, 2024 | 666,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Dec 31, 2023 | 237,000.00 |
| Dec 31, 2023 | 237,000.00 |